Genomma Lab (IFC-40144)

Countries
  • Mexico
Geographic location where the impacts of the investment may be experienced.
Specific Location
San Cayetano Morelos, Municipality of Toluca, State of Mexico
Whenever identified, the area within countries where the impacts of the investment may be experienced. Exact locations of projects may not be identified fully or at all in project documents. Please review updated project documents and community-led assessments.
Financial Institutions
  • International Finance Corporation (IFC)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Active
Stage of the project cycle. Stages vary by development bank and can include: pending, approval, implementation, and closed or completed.
Bank Risk Rating
B
Environmental and social categorization assessed by the development bank as a measure of the planned project’s environmental and social impacts. A higher risk rating may require more due diligence to limit or avoid harm to people and the environment. For example, "A" or "B" are risk categories where "A" represents the highest amount of risk. Results will include projects that specifically recorded a rating, all other projects are marked ‘U’ for "Undisclosed."
Voting Date
Apr 25, 2018
Date when project documentation and funding is reviewed by the Board for consideration and approval. Some development banks will state a "board date" or "decision date." When funding approval is obtained, the legal documents are accepted and signed, the implementation phase begins.
Borrower
GENOMMA LAB INTERNACIONAL SAB DE CV
A public entity (government or state-owned) provided with funds or financial support to manage and/or implement a project.
Sectors
  • Education and Health
The service or industry focus of the investment. A project can have several sectors.
Investment Type(s)
Loan
The categories of the bank investment: loan, grant, guarantee, technical assistance, advisory services, equity and fund.
Investment Amount (USD)
$ 54.00 million
Value listed on project documents at time of disclosure. If necessary, this amount is converted to USD ($) on the date of disclosure. Please review updated project documents for more information.
Loan Amount (USD)
$ 54.00 million
Value listed on project documents at time of disclosure. If necessary, this amount is converted to USD ($) on the date of disclosure. Please review updated project documents for more information.
Project Cost (USD)
$ 208.40 million
Value listed on project documents at time of disclosure. If necessary, this amount is converted to USD ($) on the date of disclosure. Please review updated project documents for more information.
Other Related Projects
Primary Source

Original disclosure @ IFC website

Updated in EWS Jul 10, 2018

Disclosed by Bank Feb 7, 2018

Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description
If provided by the financial institution, the Early Warning System Team writes a short summary describing the purported development objective of the project and project components. Review the complete project documentation for a detailed description.

According to the International Finance Corporation, this project consists of providing corporate financing to Genomma's expansion plan over the next two years. Genomma focuses on the marketing, distributing, and sales of over-the-counter or nonprescription medicines and personal care products.

In 2017, the compay acquired a 32 hectare lot in the town of San Cayetano Morelos to build its first production facility. It also acquired a small pharmaceutical manufacturing facility in Mexico city. Both facilities will be dedicated to finished formulations and all active pharmaceutical ingredients will be procured externally. Genomma's distribution center will be relocated to the newly constructed facility. 

Early Warning System Project Analysis
For a project with severe or irreversible impacts to local community and natural resources, the Early Warning System Team may conduct a thorough analysis regarding its potential impacts to human and environmental rights.

As of the time of writing, the Environmental and Social Review Summary on the website contained a broken link. The International Finance Corporation has identified the following areas as potential impacts of the project:

PS 1 - Assessment and Management of Environmental and Social Risks and Impacts 
PS 2 - Labor and Working Conditions 
PS 3 - Resource Efficiency and Pollution Prevention 
PS 4 - Community Health, Safety and Security 

Investment Description
Here you can find a list of individual development financial institutions that finance the project.

The purpose of the International Finance Corporation's (IFC) proposed corporate financing is to support Genomma's approximately US$208.4 million expansion plan over the next 2 years which includes the construction of Genomma's first manufacturing facility, debt refinancing, and other capital expenditures. The IFC's proposed investment is a US$54 million corporate loan to finance the construction of Genomma's first manufacturing  facility in the state of Mexico, debt refinancing, and other capital expenditures. 

Private Actors Description
A Private Actor is a non-governmental body or entity that is the borrower or client of a development project, which can include corporations, private equity and banks. This describes the private actors and their roles in relation to the project, when private actor information is disclosed or has been further researched.

The International Finance Corporation's describes the private actor as follows: "Founded in 1996, Genomma Lab Internacional S.A.B. de C.V.  is a Mexico based, pharmaceutical company listed in the Mexican Stock Exchange with presence in 19 countries across Latin America. It is focused on the marketing, distribution and sales of over-the-counter (OTC) or nonprescription medicines and personal care (PC) products.  The company does not manufacture any products yet, but works with more than 350 third-party contract manufacturers / co-packers that are US-Food and Drug Administration approved and/or have the approval of the local market where they sell their products. The company decided only recently to build its own in-house production capabilities."

Private Actor 1 Private Actor 1 Role Private Actor 1 Sector Relation Private Actor 2 Private Actor 2 Role Private Actor 2 Sector
- - - - Genomma Lab Internacional Client -

Contact Information
This section aims to support the local communities and local CSO to get to know which stakeholders are involved in a project with their roles and responsibilities. If available, there may be a complaint office for the respective bank which operates independently to receive and determine violations in policy and practice. Independent Accountability Mechanisms receive and respond to complaints. Most Independent Accountability Mechanisms offer two functions for addressing complaints: dispute resolution and compliance review.

ACCOUNTABILITY MECHANISM OF IFC

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org. You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org/

How it works

How it works